University of Cambridge > > Cambridge Oncology Seminar Series > ‘Exploring and exploiting aberrant self-fate programs in leukemia’

‘Exploring and exploiting aberrant self-fate programs in leukemia’

Add to your list(s) Download to your calendar using vCal

If you have a question about this talk, please contact Mala Jayasundera.

Host: Sakari Vanharanta (Hutchison/MRC talk)


Johannes Zuber’s lab at the Research Institute of Molecular Pathology (IMP) in Vienna develops and employs advanced RNAi- and CRISPR /Cas9-based functional genetic approaches to identify and mechanistically study cancer dependencies. Over the past years, a particular focus has been on the exploration of chromatin-associated regulators that promote aberrant self-renewal in AML and other leukemias. To identify and investigate these factors, his lab has established a panel of conditional AML mouse models and performed candidate-focused and genome-scale genetic screens for leukemia-specific dependencies. In his seminar, he will give an update on latest findings of his research.

Johannes Zuber studied medicine and received a doctorate in molecular cancer research at Charité Medical School in Berlin. Following a four-year clinical residency in hematology and oncology, he joined Scott Lowe’s lab at Cold Spring Harbor Laboratory as a postdoc, where he later was appointed as Clinical Research Fellow. In 2011, he founded his own lab at the IMP , where he develops and employs functional-genetic approaches to identify and probe candidate therapeutic targets in leukemia and other cancers. He received an ERC Starting Grant in 2015, has been selected as an EMBO Young Investigator (YIP), and has been awarded with the German Cancer Prize in 2016.

This talk is part of the Cambridge Oncology Seminar Series series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.


© 2006-2023, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity